Luke Sergott
Stock Analyst at Barclays
(2.12)
# 2,746
Out of 4,754 analysts
245
Total ratings
37.7%
Success rate
-5.61%
Average return
Main Sectors:
Stocks Rated by Luke Sergott
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ICLR ICON Public Limited Company | Maintains: Overweight | $275 → $240 | $184.81 | +29.86% | 17 | Feb 21, 2025 | |
| EXAS Exact Sciences | Maintains: Overweight | $70 → $65 | $47.55 | +36.70% | 2 | Feb 20, 2025 | |
| CRL Charles River Laboratories International | Maintains: Equal-Weight | $166 → $160 | $163.51 | -2.15% | 4 | Feb 20, 2025 | |
| SHC Sotera Health Company | Maintains: Overweight | $18 → $17 | $11.68 | +45.55% | 17 | Feb 18, 2025 | |
| BRKR Bruker | Maintains: Overweight | $65 → $60 | $46.74 | +28.38% | 2 | Feb 14, 2025 | |
| TXG 10x Genomics | Maintains: Overweight | $18 → $15 | $9.85 | +52.28% | 10 | Feb 14, 2025 | |
| WAT Waters | Upgrades: Equal-Weight | $360 → $415 | $371.79 | +11.62% | 17 | Feb 10, 2025 | |
| A Agilent Technologies | Upgrades: Equal-Weight | $135 → $145 | $126.33 | +14.78% | 7 | Feb 10, 2025 | |
| ILMN Illumina | Downgrades: Underweight | $130 → $100 | $84.20 | +18.76% | 16 | Feb 10, 2025 | |
| AVTR Avantor | Maintains: Overweight | $26 → $23 | $15.85 | +45.11% | 22 | Feb 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $135 → $140 | $110.39 | +26.82% | 8 | Feb 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $255 → $235 | $184.85 | +27.13% | 20 | Feb 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $275 → $240 | $205.69 | +16.68% | 37 | Jan 30, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $200 | $143.11 | +39.75% | 1 | Jan 23, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $60 | $40.74 | +47.28% | 1 | Jan 23, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $55 → $52 | $37.09 | +40.20% | 16 | Nov 19, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $20 → $25 | $10.38 | +140.85% | 7 | Nov 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $14 → $12 | $11.94 | +0.50% | 14 | Nov 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $620 → $610 | $523.64 | +16.49% | 23 | Oct 23, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $3 → $2 | $1.32 | +52.09% | 4 | May 10, 2024 |
ICON Public Limited Company
Feb 21, 2025
Maintains: Overweight
Price Target: $275 → $240
Current: $184.81
Upside: +29.86%
Exact Sciences
Feb 20, 2025
Maintains: Overweight
Price Target: $70 → $65
Current: $47.55
Upside: +36.70%
Charles River Laboratories International
Feb 20, 2025
Maintains: Equal-Weight
Price Target: $166 → $160
Current: $163.51
Upside: -2.15%
Sotera Health Company
Feb 18, 2025
Maintains: Overweight
Price Target: $18 → $17
Current: $11.68
Upside: +45.55%
Bruker
Feb 14, 2025
Maintains: Overweight
Price Target: $65 → $60
Current: $46.74
Upside: +28.38%
10x Genomics
Feb 14, 2025
Maintains: Overweight
Price Target: $18 → $15
Current: $9.85
Upside: +52.28%
Waters
Feb 10, 2025
Upgrades: Equal-Weight
Price Target: $360 → $415
Current: $371.79
Upside: +11.62%
Agilent Technologies
Feb 10, 2025
Upgrades: Equal-Weight
Price Target: $135 → $145
Current: $126.33
Upside: +14.78%
Illumina
Feb 10, 2025
Downgrades: Underweight
Price Target: $130 → $100
Current: $84.20
Upside: +18.76%
Avantor
Feb 10, 2025
Maintains: Overweight
Price Target: $26 → $23
Current: $15.85
Upside: +45.11%
Feb 3, 2025
Maintains: Overweight
Price Target: $135 → $140
Current: $110.39
Upside: +26.82%
Feb 3, 2025
Maintains: Overweight
Price Target: $255 → $235
Current: $184.85
Upside: +27.13%
Jan 30, 2025
Maintains: Equal-Weight
Price Target: $275 → $240
Current: $205.69
Upside: +16.68%
Jan 23, 2025
Initiates: Overweight
Price Target: $200
Current: $143.11
Upside: +39.75%
Jan 23, 2025
Initiates: Overweight
Price Target: $60
Current: $40.74
Upside: +47.28%
Nov 19, 2024
Maintains: Overweight
Price Target: $55 → $52
Current: $37.09
Upside: +40.20%
Nov 11, 2024
Maintains: Equal-Weight
Price Target: $20 → $25
Current: $10.38
Upside: +140.85%
Nov 7, 2024
Maintains: Equal-Weight
Price Target: $14 → $12
Current: $11.94
Upside: +0.50%
Oct 23, 2024
Maintains: Equal-Weight
Price Target: $620 → $610
Current: $523.64
Upside: +16.49%
May 10, 2024
Maintains: Equal-Weight
Price Target: $3 → $2
Current: $1.32
Upside: +52.09%